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ABSTRACT 
 
BACKGROUND	AND	AIMS	
Varicose veins (VVs) are the most common manifestation of chronic venous disease (CVD) 
in the Western hemisphere. Recent research shows that the disease encompasses the global 
population and with similar prevalence. The most severe form of CVD is venous ulceration 
with a prevalence of about 1% that does not only cause great suffering but is also costly for 
the society. The aims of this thesis were to investigate ways in improving prioritization, 
diagnosis, and surgical treatment of patients with VV that have the potential risk of 
developing VU. 
METHODS:	
Cross-sectional (Studies I, III and IV) and follow-up (Study II) studies were carried out. 
Study I investigated the inter-observer reproducibility of the clinical class of CEAP and 
whether there was a medical indication for treatment. Seventy-eight patients (106 limbs) 
with varying degree of CVD were included. Three independent physicians assessed the 
patients. In study II, we assessed the ulcer recurrence rate in patients with healed or active 
venous ulcer (VU) that were treated with endovenous laser ablation (EVLA) for superficial 
venous incompetence. One hundred and seventy patients (195 limbs) of consecutively 
treated patients were followed-up. Study III investigated the association between the 
biomarker E-XDP in plasma and the presence or severity of CVD. Samples of blood were 
drawn from a total of 142 patients with CVD and were matched to VU patients. In Study 
IV, 112 patients with CVD were included. The VEINES-QOL/Sym questionnaire was 
translated into Swedish and evaluated with regards to its psychometric properties.  
RESULTS	
In Study I, total agreement between the three observers for clinical class was obtained in 
61% of all cases (κ 0.55-0.68 (95% CI)) and for medical indication 60% of all cases (κ 
0.35-0.57 (95% CI)). Study II showed that all patients had healed their original ulcer 
and 84% of the limbs had no recurrence after 3.5 years. In Study III, E-XDP levels were 
elevated in patients with CVD compared with controls (p< 0.05) and increased with 
increasing disease severity (p = 0.02). Multiple linear regression confirmed that E-XDP was 
independently associated with CVI (p < 0.05) after adjustment for age and gender. Study 
IV showed excellent internal consistency for both VEINES-QOL (Cronbach’s alpha (α) = 
0.93) and VEINES-Sym (α = 0.89). Both the VEINES-QOL and VEINES-Sym correlated 
well to all the RAND-36 domains, demonstrating good construct validity. Exploratory 
factor analysis confirmed both subscales of the VEINES-QOL/Sym. 
CONCLUSIONS	
Diagnosis using the clinical class of CEAP has moderate reproducibility when deciding 
medical indication for treatment and EVLA in VU patients achieves good healing with low 
recurrence rates and low rates of complications. Further, the novel biomarker E-XDP 
appears to have a positive association with increasing disease severity. The Swedish version 
of the VEINES-QOL/Sym is valid in assessing health related quality of life in CVD, both 
clinically and in research. 
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INTRODUCTION 
 
HISTORICAL PERSPECTIVE 
The knowledge about varicose veins (VV) dates from the late fifth century BC and 
early fourth century BC when Hippocrates first described not only VV but also their 
correlation with leg ulcers (Figure 1)(1). Later on in the 16th century the French 
surgeon Ambroise Paré and Italian surgeon and anatomist Gabrielle Fallopio 
theorized that VV and leg ulcers secondary to VV were due to bad humors that if 
not treated would progress into serious illness (2).  
Treatment of varicose veins has also evolved over the years with the understanding 
of the cause of the disease. When varicose veins were treated during Hippocrates 
times, he recommended the use of bandages on the leg to produce firm compression 
and advised small punctures in varicose veins(1, 3). Surgical treatment with the 
today gold standard, high ligation and division and later addition of surgical 
stripping was first described in the early 20th century (3). The addition of stripping 
was to reduce the recurrence rates of varicose veins. Consequent treatments 
including phlebectomies, perforator vein surgery and most recent, minimally 
invasive procedures have evolved and become increasingly important(3).  
 
Figure 1. Votive plate from 
Athens, Greece.  Shows a man 
holding a huge leg with varicose 
vein. 
  
DEFINITIONS 
Chronic venous disease (CVD) as defined by the VEIN-TERM consensus document 
is “(Any) morphological and functional abnormalities of the venous system of long 
duration manifested either by symptoms and/or signs indicating the need for 
investigation and/or care”(4). Another commonly used term is chronic venous 
insufficiency (CVI), referring to advanced CVD that involves skin changes and 
venous ulceration(4).  
EPIDEMIOLOGY 
Varicose veins is the most common manifestation of CVD in the Western 
hemisphere with a prevalence that varies depending on the study at hand but can be 
approximated to 25%-33% in females and 10%-40% in male subjects(5, 6).  The 
prevalence of CVD has also been shown to be a universal condition and not limited 
to the western world(7). The prevalence of CVI is 7% for skin changes such as 
eczema, hyperpigmentation and lipodermatosclerosis and for the most advanced 
form, venous ulceration, 1%(6, 7). It is not known how common VU is globally but 
a study conducted in Brazil showed that VUs were more common in people with 
dark skin(8). Venous ulcers (VUs) are often painful, longstanding and entail high 
staff expenses due to the frequent need of dressing change and compression 
treatment (9). Overall annual costs of CVD represent 1–2% of the total healthcare 
budget in Western European countries and in the USA (10, 11).  
PATHOPHYSIOLOGY 
To better understand the pathophysiology of CVI it is important to first understand 
the normal anatomy and physiology of lower-extremity veins. There are two vein 
systems in the lower extremity, a superficial and deep vein system that are divided 
into compartments by the muscular fascia and connected by perforating veins 
(Figure 2) (12).  
The veins of the superficial compartment drain the cutaneous microcirculation and 
include the great saphenous vein (GSV), small saphenous vein (SSV) and numerous 
tributaries(13).  
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Figure 2. Deep and superficial venous compartments. Muscular fascia (MF) separates the 
superficial compartment (SC) from the deep compartment (DC). The superficial 
compartment contains saphenous veins (SV), tributary veins (TV), and accessory veins 
(AV). Saphenous veins and accompanying nerves (SN) are contained within a saphenous 
compartment that is bound superficially by saphenous fascia (SF) and deeply by muscular 
fascia. The deep compartment is bound by muscular fascia and contains the deep veins. 
Perforator veins (Perf) traverse the superficial and the deep compartments. Communicating 
veins (CV) connect veins within the same venous compartment, either deep to deep or 
superficial to superficial. Illustrated by Juliet Sinabulya 
The vein wall unlike in arteries is thin and transports blood from the periphery to the 
heart (14). With the assistance of the muscle pump in the extremities, blood flows in 
a forward direction and bicuspid valves in the veins prevent retrograde flow (reflux) 
(Figure 3) (15).  
                    
 
Figure 3. Normal and pathological vein structure. Illustrated by author. 
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The pathophysiology of CVI is characterized by increase in venous pressure 
impairing the return of blood flow to the heart(16). This is a result of either reflux, 
obstruction or both and is exacerbated by muscle pump dysfunction in the lower 
extremity(14). Reflux may either be of primary or secondary etiology. Primary CVI 
is considered to be a result of an underlying connective tissue defect perceived as 
valvular incompetence or destruction and dilated veins leading to increased 
ambulatory venous pressure(5, 17).  
Secondary CVI may be due to previous deep vein thrombosis (DVT), with an 
annual incidence of 0.1% and affects 2-5% of the population in a lifetime (18). An 
estimate of 25-50% develop a complication to DVT called post-thrombotic 
syndrome (PTS), resulting from incomplete lysis of thrombus that causes fibrosis 
and obstruction that may destroy the vein valves (19). PTS may present as CVI 
including skin changes and venous ulceration (20). 
At the microcirculation level; venous hypertension, mechanical injury or stress due 
to the vein structure induces capillary leakage allowing the accumulation of several 
circulating products such as fluids, red blood cells and protein(16). Degradation of 
red blood cells and protein extravasations initiate an inflammatory reaction resulting 
in leukocyte migration leading to the complications ranging from edema and 
lipodermatosclerosis to tissue necrosis and venous leg ulceration (Figure 4)(21).   
 
 
Figure 4. Leukocyte adhesion and migration due to venous hypertension. Reproduced with 
permission from Dr Fatih Islamoglu, Turkey. 
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VENOUS ULCER 
Venous ulceration being the most severe form of CVD, resulting in a lot of pain and 
suffering plus great costs to society, renders much attention.  It is still unclear why 
some people develop VUs secondary to VVs (primary CVI) or DVT (secondary 
CVI), thus making the clinical diagnosis more complex and difficult to predict 
which patients are at a higher risk of developing venous ulceration. 
Studies on VU have shown that chronic inflammation is the main cause(17, 22, 23). 
One theory being through leukocyte activation that damages connective tissue and 
the skin in the leg(24).  Another is interepithelial pore widening that allows the 
deposition, of fibrin and other macromolecules that would otherwise aid in wound 
repair, to the dermis(25). The pathophysiology behind the inflammation on a 
microcirculation level is as described under Pathophysiology and can be 
summarized as secondary to persistent elevation of ambulatory venous pressure(26).  
The presentation is normally over bony prominences, particularly in the gaiter area 
(ankle to mid-calf) and they are generally irregular, despite well defined borders, 
shallow with red granulation tissue and fibrin slough (yellow-white exudate) in the 
ulcer base(27). Another common presentation is the “champagne bottle deformity” 
perceived as contraction of the subcutaneous tissues of the gaiter area (Figure 5) 
(23).  
 
Figure 5. Chronic VU characterized by inflammation surrounding the ulcer, irregular ulcer 
border, and wound bed with granulating matrix. There is excess drainage from the venous 
leg ulcer rich in cytokines and proteinases that exacerbate a condition of inflammation. You 
can even see tendency to “champagne bottle deformity”. Photo by Lena Blomgren 
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The baseline treatment of VU for thousands of years has similarly to VVs been 
compression (28). However, well-conducted randomized trials have shown that 
surgical treatment of VV complemented with compression reduces the risk of ulcer 
recurrence (29, 30). Other treatment forms include topical treatments such as silver 
sulphadiazine, cadexomer and oasis matrix, all studied in randomized trials and 
shown to improve ulcer healing(23). Even anti-inflammatory drugs have shown in 
several studies to improve microcirculation of the leg and thus aiding in the healing 
process(27). 
BIOMARKERS FOR CHRONIC VENOUS DISEASE 
Due to the gap in knowledge on etiology of VU whether secondary to VV or DVT, 
we seek methods to help improve prioritization when it comes to patient selection 
for surgery. Finding a biomarker with direct association with CVI could become a 
possible predictor of disease(31). 
We have understood that inflammation almost certainly plays a role in CVI but 
there are few studies that have evaluated the direct association between specific 
biomarkers and venous disease(22). We also know that venous ulceration involves 
coagulopathy including thrombophilia but the causal relationship between VU and 
coagulopathy remains difficult to clarify(32, 33). 
Smith et al reviewed the current literature on the association of circulating markers 
with primary CVI and identified three that were linked to alteration of vascular wall 
homeostasis; homocysteine, vascular endothelial growth factor (VEGF) and 
estradiol (34). Homocysteine is realized as a biomarker that increases endothelial-
leukocyte interaction and venous thromboembolism development(35, 36). VEGF 
affects vascular tone and when plasma levels were examined in correlation with 
clinical class they have been shown to have a positive trend towards higher levels 
compared to controls but with statistical significance only in patients with healed 
ulcers(37). Elevated serum levels of estradiol, which too affects vascular tone, in 
both men and women have also been shown to be associated with VV(38, 39). 
Another well studied thrombolysis-related and clinically used biomarker in patients 
with venous thromboembolism is D-dimer(40). It is elevated and widely used 
clinically in many diseases such as DVT, pulmonary embolism and more(41, 42).  
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A novel biomarker for the activation of leukocytes, cross-linked fibrin degradation 
products (XDP), has been shown to be elevated in patients with venous 
thromboembolism but there is no data on levels in patients with CVI(40, 43). XDP 
is produced specifically when neutrophil elastase breaks down fibrin that is present 
in thrombus (Figure 6) (44). This is of special interest in the development of venous 
ulceration as this involves both thrombosis and the activation of leukocytes. 
 
 
 
Figure 6. Tissue plasminogen activator (tPA) activates Plasminogen to Plasmin that 
cleaves fibrin, forming fibrin degradation products (FDPs). Plasminogen activator 
inhibitors (PAIs) are elevated during inflammation. Leukocyte elastase, released from 
activated leukocytes, digests fibrin yielding cross-linked FDPs (XDP) that are different 
from those yielded from Plasmin. Adapted from Bhattacharjee et al ©(45). 
 
D-dimer is also a fibrin degradation product that unlike elastase mediated XDP is a 
digest of Plasmin(46). A draw back of this marker is its lack of specificity in 
positive cases of venous thromboembolism(47). Thus the need of a more specific 
biomarker with regards to CVD. 
All in all, it is suggested that the pathogenesis of CVI is multifactorial and complex 
and that biomarker research aids the clinician by improving the current knowledge 
on prognostic information on CVI(34). 
Leukocyte Elastase  XDP 
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DIAGNOSIS 
CLINICAL EXAMINATION 
The American Venous Forum met in Hawaii, 1994 and agreed upon a consensus 
document to be used for the classification of chronic venous diseases and a scoring 
system of the severity of CVD(48). The CEAP classification (Clinical-Etiology-
Anatomy-Pathophysiology) was formed and is widely used clinically and in 
research(49). It was revised in 2004, creating the basic CEAP (Table 1) and is today 
gold standard for classification of CVD(50, 51). Nonetheless the CEAP has been 
shown to have a moderate inter-observer reproducibility(49).  
The CEAP classification provides a descriptive tool for patients with CVD but has 
also been critiqued for lack of consistency with common symptoms such as pain and 
lack of responsiveness when evaluating patients in the long term(52, 53). 
Venous Clinical Severity Score (VCSS) is the scoring system also included in the 
consensus document above(48). The VCSS is one of three venous severity scores 
that grade the clinical symptoms of venous disease. The other two are Venous 
Segmental disease score (VSDS) that grades anatomic and patho-physiologic 
symptoms and Venous Disability Score (VDS) which is an extension of CEAP and 
evaluates the ability to work(54). The most widely used is VCSS, complementing 
the CEAP and correlates to health related quality of life (HRQoL) measures(55).   
In conjunction with clinical examination, established risk factors such as age, 
female gender, multiparity, family history, obesity, and occupations associated with 
prolonged standing should be included(56).   
Table 1. Clinical class of CEAP (Clinical-Etiology-Anatomy-Pathophysiology) 
C class Description 
Class 0 No visible or palpable signs of venous disease 
Class 1 Telangiectasies, reticular veins, malleolar flare 
Class 2 Varicose veins; diameter ≥ 3 mm 
Class 3 Edema without skin changes 
Class 4 Lipodermatosclerosis or atrophie blanche 
Class 5 Skin changes with healed ulceration 
Class 6 Skin changes with active ulceration 
Adapted from Eklöf et al. (50)  
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DUPLEX ULTRASOUND 
In addition to physical examination of patients with CVD, it is also recommended 
that duplex ultrasound scanning (DUS) of both the deep and superficial veins be 
performed as the primary diagnostic method(57). The method is accurate, safe and 
non-invasive and if performed as routine preoperative investigation, it has been 
shown to improve surgical results of uncomplicated VV(58). With DUS you can 
achieve information about flow and hemodynamic parameters such as refilling time, 
velocity at peak reflux, vein diameter and volume flow(59).  
Reflux is considered significant if longer than 500 ms for superficial veins and for 
popliteal and femoral veins the cut-off is 1 second(57). This is the time required by 
the initial reflux of blood to bring normal valve leaflets into apposition. The official 
definition of perforator vein reflux is if longer than 500 ms but this doesn’t 
necessarily mean pathological significance and in clinical practice pathology is 
considered if the perforating vein is dilated with outward flow and in near vicinity to 
skin changes or VU(60-62). 
DUS is also used in the diagnosis of DVT(63). One should note though that when 
examining the deep veins of the lower leg, DUS has been shown to have a lower 
reliability on investigating patency, obstruction or occlusion(64). However, the 
reverse was shown for the femoro-popliteal veins(65). When DUS was compared to 
air plethysmography, another non-invasive technique used in evaluation of CVI, 
there was good reproducibility of measurements by the two techniques(66).  
PHOTOPLETHYSMOGRAPHY 
A complementary examination to DUS in the diagnosis of CVD is 
photoplethysmography (PPG), a method in which the transmission of light 
reflection in the subdermal venous plexus is detected as a measure of the change of 
blood volume in the skin(67). The advantage of PPG is that it’s a non-invasive, 
cheap, simple and sensitive test suitable for outpatient use(68). It offers a 
quantitative measure of venous reflux (refill time) as a complement to DUS, which 
on it’s own shows the anatomical distribution of VV(69, 70).  
As PPG doesn’t have good relation between refill time and venous disease severity, 
DUS remains superior to PPG as it gives more information than refilling time as 
Helen Sinabulya 
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explained under “Duplex Ultrasound”(71). The combination of PPG, clinical 
examination and DUS could possibly improve the prioritizing of VV patients. 
PRIORITIZATION 
Several studies have shown that there is a correlation between venous hypertension 
and CVD symptoms and signs including heaviness, swelling, aching and cramps but 
this association has been inconsistent between patients(72-74). This additionally 
complicates clinical practice when predicting which patients with VV are at risk of 
developing a VU in future. We know that surgical treatment of VV in patients with 
VU reduces the risk of ulcer recurrence(29).  
The current recommendations in several Swedish county councils allow 
reimbursement for surgery in cases of VU, skin changes and where severe 
symptoms affect HRQoL negatively. Although there is a correlation between 
venous hypertension and CVD signs and symptoms, several studies have shown that 
there is a poor correlation between leg symptoms and extent of superficial venous 
pathology on DUS(74, 75). This may lead to difficulties in patient assessment for 
the treating surgeon in the case of a patient with severe symptoms but no skin 
changes resulting in a conflict of opinion on whether the surgery should be 
reimbursed by the county council or not(57). 
The clinical class C of CEAP is the basis for the Stockholm county council’s 
recommendations on reimbursement, but as mentioned previously, it was last 
revised in 2004 and has been shown to have a moderate inter-observer reliability(49, 
76). Another issue is allocation of government resources to the care and treatment of 
VV patients where it has been shown that VV wait for their surgery longer than 
gallstones or inguinal hernia (77). This may also be explained by the fact that VV 
often have low priority and have been referred to as the “Cinderella” of surgery(78). 
QUALITY OF LIFE MEASURES IN VENOUS DISEASE 
The most severe form of CVD, VU is both costly for society and painful for the 
patient (9).  As many as 10% of the adult British population suffers from depression 
at any one time and depression is twice as common in CVD patients (79). It has 
been shown that VV without skin changes cause a reduced quality of life 
comparable to gallstones and inguinal hernia (80). According to the European and 
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American clinical practice guidelines, the assessment of CVD should also include 
quality of life evaluation (53, 57).  
Currently there are several generic and disease-specific instruments used to measure 
HRQoL, clinically and for research purposes. Among the widely used generic 
instruments are the Short Form 36-Item Health Survey and EuroQoL-5D (EQ-
5D)(81).  Some of the most popular and validated disease-specific instruments are 
the Aberdeen Varicose Veins Questionnaire (AVVQ), Chronic Venous 
Insufficiency Questionnaire (CIVIQ) and the VEnous Insufficiency Epidemiological 
and Economic Study on Quality of Life/Symptoms (VEINES-QOL/Sym) (55).  
The AVVQ is sensitive in assessing functional outcome after treatment for chronic 
venous disease and CIVIQ is a tool created for C0 - C4 patients and unlike the 
AVVQ, it takes into account the more psychological effects on quality of life(82). 
VEINES-QOL/Sym evaluates quality of life and symptoms for the whole spectrum 
of venous disease, from telangiectasies to skin changes and VU(55). 
Even with several validated disease-specific HRQoL instruments in many 
languages, there is no such instrument for CVD in Swedish, and it is needed both 
for research purposes and for clinical evaluation. 
TREATMENT IN CHRONIC VENOUS DISEASE 
There are a variety of treatment methods available for patients with CVD and the 
commonly recommended treatment of VVs is compression but with a compliance 
that varies between 30 % and 65% (83).  The gold standard treatment for VVs in the 
GSV has been surgery with high ligation (HL) and division at the confluence of the 
GSV and the femoral vein and the addition of stripping has either been performed 
consequently or later (3). VVs in the SSV have also traditionally been treated with 
HL at the confluence of the SSV and popliteal vein (84). 
During the last decade minimally invasive techniques such as Endovenous Laser 
Ablation (EVLA), Radiofrequency Ablation (RFA) and Ultrasound-guided Foam 
Sclerotherapy (UGFS) have gained popularity over conventional surgery (85). 
These techniques have the advantage of being able to be performed in local 
anesthesia and thereby allowing even elderly patients with comorbidities treatment 
(86). Even with this knowledge, clinical experience shows that few patients with 
VU are referred directly for surgical intervention upon presentation; rather they are 
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often treated conservatively for years with recurring ulcers before referral. The 
reason for this is uncertain but one may speculate that the physicians who these 
patients often first seek help from are not aware of current guidelines or that they 
believe that the ulcer must first heal before consideration for surgery and that 
surgical treatment may be too invasive for this patient group. 
When EVLA and RFA have been compared to conventional surgery, studies have 
shown that it is as effective (87). In clinical practice EVLA and RFA are 
increasingly used to treat patients with VU and there are several reports about low 
recurrence rates but with small groups and short follow-up(88),(89).  
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AIMS OF THE THESIS 
 
RATIONALE  
In this thesis, aspects of diagnosis, treatment and evaluation of chronic venous 
disease (CVD) are studied. VU the most severe form of CVD is a great burden both 
for the society as well as for the diseased patients. 
The American and European venous disease guidelines have been formed to guide 
in diagnosis and treatment and create a broad basis for further research. One much 
needed area of research is biomarkers and CVI, that have and are currently being 
studied. The question being; is there a need for a novel biomarker within the field of 
CVD. Health related quality of life scoring is another recommendation for 
evaluation of CVD; is there a need for a scoring questionnaire in Swedish?  
OVERALL AIM OF THE THESIS 
To investigate ways in improving prioritization, diagnosis, and surgical treatment of 
patients with VV that have the potential risk of developing VU. This has been done 
by way of four studies. 
SPECIFIC AIMS 
Ø Study I: To test the inter-observer reproducibility of the clinical class of 
CEAP when used in a clinical setting where the patients’ clinical signs and 
symptoms were evaluated if severe enough for treatment within the national 
health insurance system. 
Ø Study II: To assess the ulcer recurrence rate after a longer follow-up in a 
larger cohort of patients with healed or active VU treated with EVLA for 
superficial venous incompetence (SVI) and to search for possible risk factors 
for non-healing or recurrence. 
Ø Study III: To investigate the association between the biomarker E-XDP in 
plasma and the presence or severity of CVD. 
Ø Study IV: To translate and evaluate the psychometric properties of the 
VEINES-QOL/Sym in a Swedish cohort of patients with venous disease. 
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PATIENTS AND METHODS 
 
OVERVIEW OF STUDY DESIGN 
In Table 2 is a summary of the study design, population and statistical methods in 
this thesis. 
Table 2. Overview of studies 
Study Design Study population Statistics 
Study 1 Cross-sectional 
cohort study 
78 Consecutive patients 
106 limbs 
Kappa-analysis 
Study II Follow-up study 170 patients, 195 limbs 
 
Chi-square, Fishers 
exact test and Students 
t-test  
Logistic regression 
analysis 
Study III Cross-sectional 
cohort study 
142 patients matched for 
age, gender and C class 
 
Students t-test and 
ANOVA 
Multivariate linear 
regression analysis 
Study IV Cross-sectional 
cohort study 
112 Consecutive patients 
 
Exploratory factor 
analysis 
Reliability and 
correlation analysis 
ANOVA; Analysis of variance 
PATIENTS 
All patients included were recruited from Venous Centre (VC), a high volume 
centre in Stockholm, Sweden, dedicated to the treatment of varicose veins. In all but 
study II, consecutive patients were asked to participate and in study II patients were 
identified from the medical records and quality registry. In study III included 
patients were matched between the C-classes and those graded as C-class 0 or 1 and 
without history of DVT were used as controls.  
At the time of the studies, VC treated patients who were reimbursed by the 
Stockholm County or by insurance companies, and also patients who paid for the 
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treatment themselves. The clinic treated all C classes and were reimbursed for 
classes C3-6 with the addition of patients with nonspecific symptoms such as 
heaviness, tingling and pain if (i) there was no other etiology to the mentioned 
symptoms, (ii) the HRQoL was clearly affected, (iii) treatment with compression 
relieved symptoms and (iv) if significant reflux was seen on DUS, Doppler or any 
other quantitative investigation of the venous system (Table 3). 
Upon inclusion, all patients were graded according to the C class of CEAP 
classification and in studies II-IV history of DVT was also asked.  
A drawback with using a private clinic for research that receives reimbursement 
from the local county is that during certain periods of the year, very few if any 
patients with CVI would be treated. This due to need for annual renegotiations of 
reimbursement fees that could at times take months and after which would result in 
less fees than actual patient load.  
ETHICAL CONSIDERATIONS 
The Regional Ethical Review Board in Stockholm approved all the studies. All 
patients received written information and signed a consent form before 
participation.  
In Sweden, many CVD patients are now treated in private clinics, so for research 
purposes it was easier to recruit patients from such a centre. In study I and II, patient 
inclusion was not as difficult since these patients sought initial care or follow-up 
after treatment. In study III and IV there was more of a challenge due to the nature 
of the studies that may be more difficult for the patient to perceive the direct 
importance at their actual time of consultation. When it came to patient recruitment 
of controls in study III, this proved to be the biggest challenge as these were 
perfectly healthy patients with minor or if any physical symptoms being asked to 
take extra time and to undergo, even if minor, an invasive investigation. 
METHODS 
STUDY I 
The study took place between August 2011 and February 2012. All patients were 
evaluated with regards to whether there was a medical indication for treatment 
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according to the Stockholm County guidelines, set in 2005 (Table 3). Exclusion 
criteria were: patients not willing to participate in the study, CEAP classification 
done previously, language problems or dementia.  
Three physicians, consisting of a surgical resident, a consultant vascular surgeon 
from a university hospital and a consultant vascular surgeon from the private clinic, 
assessed the patients independently and their respective assessments were blinded to 
each other. The assessment was with regard to C class of each patient and whether 
there was a medical indication for treatment. This choice of having physicians with 
different backgrounds and levels of experience was intentional as it better reflects 
the every day care of CVD patients all over the nation. Another option could have 
been to invite a general physician to partake or a general surgeon who do not treat 
VV patients but encounter such cases on a day-to-day basis.  
Upon examination the patients were given license to describe their own symptoms 
and were examined by each physician to see if there was a medical indication for 
treatment according to the Stockholm County guidelines. DUS was performed on all 
patients to confirm the presence of superficial venous insufficiency, and to exclude 
patients with post thrombotic changes. 
Table 3. Distinctions between medical and cosmetic indication for treatment of VV by the 
expert surgical committee in Stockholm County 2005-12-01 
Grade Symptoms Medical Indication 
1 Venous ulcer Yes 
2 Venous eczema /stasis pigmentation Yes 
3 Edema, thrombophlebitis, VV with bleeding Yes 
4 Nonspecific symptoms (heaviness, tingling, pain, etc.) Yes* 
5 VV without symptoms (cosmetic) No 
6 Telangiectasies (cosmetic) No 
* If no other etiology to symptoms, HRQoL clearly affected, if treatment with compression 
relieves symptoms and if significant reflux on DUS, Doppler or any other quantitative 
investigation of the venous system. 
STATISTICAL	ANALYSIS	
Sample size was calculated to a minimum of 51 limbs with three raters if we wished 
to demonstrate that the reliability coefficient ρ > 0.4 with 80% power for a 
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significant result at α=0.05 when ρ=0.6(90). Cohen’s kappa, k, and weighted kappa 
were used when analysing agreement between pairs of examiners for C of CEAP. 
Kappa agreement was interpreted as slight (κ = 0.0–0.20), fair (κ = 0.21–0.40), 
moderate (κ = 0.41–0.60), substantial (κ = 0.61–0.80), and almost perfect (κ = 
0.81–1.0)(91). Fleiss kappa, k, was used to measure the inter-observer agreement 
between all three examiners for both C of CEAP and medical indication(92).  
STUDY II 
In this study recruitment was between April 2013 and February 2015. The main 
treatment methods at the clinic at time of the original treatment were EVLA, 
ambulatory phlebectomies and UGFS.  
Patients treated with EVLA for SVI, and who at the time of treatment had a healed 
or open VU, clinical class C5 and C6 were invited to participate in the study. Figure 
2 shows the flow of patients.  
 
Figure 2. Chart showing the flow of patients through the study 
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At the follow-up examination medical history was taken from the patient including 
several risk factors and postoperative complications such as DVT, infection and 
nerve injury. Generic HRQoL scoring was measured using the (EQ-5D)(93). Ankle 
brachial pressure index (ABPI), PPG, DUS and evaluation with venous clinical 
severity score (VCSS) were also performed.  
STATISTICAL	ANALYSIS	
Chi-square, Fisher’s exact test and t-tests were used to compare proportions between 
the original C5 and C6 groups, and to compare patients with and without recurrent 
VU at follow-up. Level of statistical significance was considered p < 0.05. Logistic 
regression was used in the multivariate analysis to identify independent risk factors 
for ulcer recurrence. 
STUDY III 
Patient recruitment was between January 2015 and April 2016. Included patients 
were asked about any current medication with a statin or anticoagulant. Thereafter 
samples of peripheral blood were drawn preceding surgical treatment.  
ENZYME-LINKED	IMMUNOSORBENT	ASSAY	 	
The blood samples taken were used to measure plasma levels of cross-linked fibrin 
degradation products by leukocyte elastase (E-XDP). This was done using a 
sandwich enzyme-linked immunosorbent assay (ELISA) as described by Kohno et 
al(94). The monoclonal antibody anti-E-XDP clone IF-123 (Cosmo Bio Co. Ltd., 
Tokyo, Japan) was used as capture antibody since it specifically recognizes elastase-
digests of human fibrinogen and fibrin, but not their plasmin-digests(95). 
Horseradish peroxidase-labeled anti-human fibrinogen rabbit antibody (DAKO, 
Glostrup, Denmark) was used as probing antibody. 
 For further characterization of the antibody IF-123, we incubated fibrinogen 
(3mmol/L) with elastase (Product E-8140, Sigma), plasmin or reaction buffer alone 
(0.05M Tris, 0.15M NaCl, pH 8.0), proteases at 88 nmol/L. Samples were taken 
with minutes intervals for 1 hour and treated with excess of protease inhibitor 
cocktail (complete, mini, EDTA-free, from Roche). Samples were thereafter 
analyzed for reactivity in the ELISA described above. Incubation of fibrinogen with 
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elastase generated product(s) that reacted in the ELISA with IF-123 (seen as 
increase in optical density, in the samples taken after 40 minutes incubation), which 
did not occur with incubation with plasmin or buffer alone. 
STATISTICAL	ANALYSIS	
The binary logarithm of E-XDP concentration (simply referred to as E-XDP) was 
used in all analyses. Differences of means between two groups were examined for 
statistical significance using the Student’s t-test for independent samples. A p-value 
less than 0.05 denoted the presence of a statistically significant difference. Multiple 
linear regression was used to study the association between plasma E-XDP 
concentrations and severity of CVD. 
STUDY IV 
Patients with varying degrees of CVD were recruited in May 2016. Data was 
collected including age, gender and history of previous VV surgery. All patients 
were provided with a copy of both the Swedish VEINES-QOL/Sym and the RAND 
36-item health survey (RAND-36) to complete.  
TRANSLATION	AND	TESTING	
The questionnaire was translated into Swedish with forward-backward translation as 
described by Beaton et al. (96). Three researchers with special interest in 
Phlebology were involved in the total process. The resulting Swedish VEINES-
QOL/Sym (VEINES-QOL/Sym-Swe) became the final version administered to the 
study population and used to evaluate reliability and validity. 
STATISTICAL	ANALYSIS	
Feasibility of the questionnaire was assessed by the overall response rate. Floor and 
ceiling effects were checked (i.e., response categories with high endorsement rates 
at the bottom/top ends of the scale, respectively) for summary scores. Descriptive 
baseline characteristics were presented as means and standard deviations (SD) or 
numbers and percentages (%) as appropriate. A two-sided p value of <0.05 was 
considered statistically significant. 
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Reliability in the context of health outcome measurement is the ability of the 
instrument to measure its subject consistently. This was tested using the reliability 
coefficient Cronbach’s alpha (α) that assesses internal consistency. Structure of the 
VEINES-QOL/Sym was tested using exploratory factor analysis. Factor analysis is 
a statistical method that is used to explain whether or not the pattern of responses on 
a number of items can be explained by a smaller number of underlying factors(97). 
Good structure was if items loaded a value higher than 0.35. 
Construct validity assesses whether the scales scores behave as predicted according 
to existing knowledge about the population and the disease and involves 
comparisons with other variables. Convergent validity that is a form of construct 
validity tests whether the score has positive relationships with other quality of life 
and well-being scales. This was tested using the Spearman’s rank correlation 
coefficient. Another adjunct to construct validity is known-group differences that 
are used to compare two groups that are known to have certain results from previous 
studies.
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RESULTS 
 
STUDY I 
- The reproducibility of C when deciding medical indication for treatment is 
moderate. 
The majority of the included patients (85.9%) were female and the median age of 
the study-patients was 58.5 years (range= 23-91). The C-class distribution of 
patients for each respective observer is shown in Table 4. 
Table 4. Number of limbs in each C class for each respective observer and number in total 
agreement 
C class Observer 1 Observer 2  Observer 3  Total 
Agreement  
Kappa Z P(vs > 0) 
0  2  3  3  2  0.74 13.3 <0.001 
1  20  21  18  16  0.82 14.6 <0.001 
2  43  38  48  30  0.57 10.2 <0.001 
3  5  7  6  0  0.17 3.1 <0.001 
4  28  39  24  14  0.56 10.0 <0.001 
5  3  2  2  1  0.71 12.6 <0.001 
6  2  3  2  2  0.85 15.2 <0.001 
 
The numbers in Table 4 are similar; however, the numbers in each class do not 
necessarily represent the same patients. Least agreement was seen for class C3, 
followed by C2 and C4. The agreement between pairs of examiners for all clinical 
classes of CEAP is shown in Table 5. 
Table 5. Exact agreement between examiners for C class of CEAP  
Observers Agreement (%) 95% CI Wκ (95% CI) 
All 61.3 51.4-70.6  
    1 vs 2 78.3 69.2-85.7 0.82 (0.73-0.92) 
1 vs 3 67.9 58.2-76.7 0.76 (0.65-0.87) 
2 vs 3 70.8 61.1-79.2 0.75 (0.63-0.86) 
CI = confidence interval; Wκ = weighted kappa. 
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The agreement between pairs of examiners concerning medical indication for 
treatment is shown in Table 6. 
Table 6. Exact agreement between examiners for medical indication for treatment 
Observers Agreement (%) 95% CI 
All 60.4 50.4-69.8 
   
1 vs 2 78.3 69.2-85.7 
1 vs 3 66.0 56.2-75.0 
2 vs 3 76.4 67.2-84.1 
CI = confidence interval. 
STUDY II 
- Midterm follow-up after endovenous laser ablation of superficial venous 
incompetence in patients with healed or active venous ulcers achieves good healing 
The mean follow up time was 41 months (range 14-89). The mean age at the time of 
operation was 62.4 ± 11.2 years (mean ± standard deviation) in the C5 group and 
64.1 ± 10.5 years in C6 (p = 0.265). The male/female ratio was 42/52 in C5 and 
30/46 in C6 group (p = 0.761). Demographics and characteristics of patients/limbs 
are shown in Table 7.  
Table 7. Demographics and characteristics, comparing subjects with healed and open ulcer 
at the time of EVLA treatment 
 Total C5 group* 
 
C6 group** 
 
P value 
Patients 170 94 76  
DM 14 (8%) 7 (7%) 7 (9%) 0.797 
CVD 35 (21%) 17 (18%) 18 (24%) 0.414 
Smoker 13 (8%) 5 (5%) 8 (11%) 0.307 
No. of Limbs 195 109 86  
EVLA of GSV 158 (81%) 91 (83%) 67 (78%) 0.324 
EVLA of SSV 50 (26%) 22 (20%) 28 (33%) 0.049 
EVLA of AASV 16 (8%) 11 (10%) 5 (6%) 0.280 
EVLA of PV 2 (1%) 2 (2%) 0 (0%) 0.504 
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The patients' characteristics did not differ between the C5 and C6 groups; therefore 
limbs from both groups were grouped together to compare parameters according to 
ulcer recurrence. 
The only significant differences between the original C5 and C6 limbs were a 
slightly longer follow-up (18 days) (p = 0.013) in the C6 group and more limbs 
operated with EVLA of the SSV (p = 0.049). Limbs with recurrent VU had a 
statistically significant association with male sex (p = 0.026), lower HRQoL (p = 
0.037), higher VCSS score (p < 0.001), reduced ankle mobility (p = 0.047) and 
impaired venous function (p  = 0.029) with lower venous refill times, all in the 
univariate analysis. Further analysis was conducted to assess risk factors for 
recurrence with logistic regression. Variables included were perforator vein 
insufficiency (PVI), VV in the ulcer area, deep venous reflux and reduced ankle 
mobility.  The only variable significantly associated with ulcer recurrence was 
reduced ankle mobility (p = 0.048).  
STUDY III 
- There are increased plasma levels of cross-linked fibrin degradation products by 
leukocyte elastase (E-XDP) with increasing disease severity.  
The mean age was 63.53 years, (range 23-89), 81 were females and 61 males. 
Patient demographics and characteristics are shown in Table 8. C-class was used to 
group the patients on analysis, C 0-1 were controls, C 2-3 was the second group and 
C 4-6 the third group. 
Table 8. Patient characteristics and demographics 
 C0-1 (n=10) C2-3 (n=41) C4-6 (n=91) 
Age (years), mean (SD) 58.2 (13.9) 61.0 (13.7) 64.6 (13.3) 
Gender, n (%)    
Female 9 (90) 27 (65.9) 45 (49.5) 
Male 1 (10) 14 (34.1) 46 (50.5) 
History of DVT (%) 0 1 (2.4) 9 (9.9) 
Use of Statin (%) 0 0 15 (16.5) 
Use of anticoagulant (%) 0 6 (14.6) 25 (27.5) 
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The following clinical features were analysed using univariate analysis before 
subjection to multiple linear regression: age (p < 0.001), gender (p = 0.708), use of 
statins (p < 0.001), anticoagulants (p < 0.001) and history of DVT (p = 0.015). 
Multiple linear regression confirmed that E-XDP was independently associated with 
CVD (p < 0.05) after adjustment for age and gender (Figure 1). However, after 
adjustment for differences significant in univariate analysis such as use of statins, 
anticoagulants and history of DVT, the previous association was not seen between 
higher concentrations of E-XDP and CVD. 
 
Figure 1. Concentration of E-XDP between groups of chronic venous disease 
STUDY IV 
- The Swedish VEINES-QOL/Sym showed excellent internal consistency for both 
VEINES-QOL and VEINES-Sym. 
The included patients were classified according to the C-class of CEAP and 6% 
were classified as C1, 46% as C2, 7% as C3, 25% as C4, 9% as C5 and 6% as C6. 
Missing values for both questionnaires were less than 10%, indicating good 
feasibility. There were no apparent floor or ceiling effects for the VEINES-
QOL/Sym questionnaire.  
P= 0.001 
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The mean age was 54.5 ± 15.2 years (range 19 – 83) and patient characteristics are 
shown in Table 9. 
Table 9. Patient characteristics and clinical data 
Characteristics N (112) % 
Gender    
Male 28 25 
Female 84 75 
Age (years)   
Mean ± SD (range)  54.5 ± 15.2 (19 - 83) 
Previous VV surgery   
Yes 45 40 
No 67 60 
History of DVT   
Yes 10 8.9 
No 102 91.1 
 
The Cronbach’s alpha coefficient showed an excellent internal consistency for both 
VEINES-Sym and VEINES-QOL, measures were α = 0.89 and α = 0.93 
respectively. 
The factor analyses showed that the VEINES-Sym items fit the structure well (Table 
10). All but item 1h (´during the past 4 weeks, have you experienced itching in the 
affected leg(s), loading of 0.334´) of the 25 items of the VEINES-QOL fit the 
structure well. Our results were compared with the Dutch results and the patterns of 
factor loadings were similar between the Swedish and the Dutch version(98). 
The three researchers tested content and face validity and agreed that the VEINES-
QOL/Sym covers central aspects of CVD.  
Comparing the VEINES-QOL/Sym scores with the RAND-36 subscale scores 
tested construct validity. The strongest correlation when it came to VEINES-Sym 
was noted with the RAND-36 subscale, bodily pain (BP) (r = 0.76; p < 0.01). When 
it came to the VEINES-QOL, the strongest correlations were noted with the RAND-
36 subscales BP (r = 0.82; p < 0.01) and physical function (PF) (r = 0.66; p < 0.01).  
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Table 10. Factor loadings of an exploratory ordinal factor analysis (SWE)* 
Items VEINES-Sym VEINES-
Sym/QOL 
SWE NL SWE NL 
q1a Heavy legs .764 0.61 .730 0.54 
q1b Aching legs .882 0.73 .762 0.59 
q1c Swelling .585 0.46 .440 0.38 
q1d Night cramps .570 0.49 .530 0.43 
q1e Heat or burning sensation .677 0.64 .502 0.52 
q1f Restless legs .731 0.65 .652 0.50 
q1g Throbbing .740 0.63 .553 0.58 
q1h Itching .410 0.46 .334 0.40 
q1i Tingling sensation .771 0.68 .601 0.55 
q7 Intensity of leg pain .736 0.71 .714 0.62 
q3 Compared to one year ago …rate your leg 
problem 
  .451 0.31 
q4a Daily activities at work   .724 0.56 
q4b Daily activities at home   .722 0.79 
q4c Standing for long periods   .749 0.68 
q4d Sitting for long periods   .673 0.66 
q5a Cut down time spent on work   .524 0.75 
q5b Accomplished less   .678 0.76 
q5c Limited in kind of work   .626 0.56 
q5d Difficulty performing work   .692 0.67 
q6 Interference with normal social activities   .775 0.77 
q8a Concerned about appearance of leg(s)   .357 0.29 
q8b Felt irritable   .660 0.66 
q8c Felt a burden   .703 0.55 
q8d Worried about bumping into things   .532 0.41 
q8e Appearance of leg(s) influenced choice of 
clothing 
  .362 0.35 
NL; See S K van der Velden et Al: Translation and validation of the Dutch VEINES-
QOL/Sym in varicose vein patients. Phlebology 2014; 29: 227–235, Table 2. 
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To examine known-group differences we hypothesised that disease severity would 
correlate with poor HRQOL but this was not confirmed. There were no statistically 
significant differences found between the VEINES-Sym (p = 0.57) and VEINES-
QOL (p= 0.22) mean scores and the severity of CVD even if there was a trend for 
lower VEINES-QOL scores with increasing severity of CVD classified as worst C-
class of CEAP.  
 
 
 
 
 
 
 
 
 
 
 GENERAL DISCUSSION 
 
This thesis aimed to highlight some of the challenges on the topic of CVD. 
Diagnosis and prioritization that are discussed in study I, III and IV are of great 
importance not only for the health care system/budget but also for the suffering 
patients. Evaluation of a relatively new treatment method for VU patients and 
introduction of a disease-specific patient reported outcome measure (PROM) in 
Swedish as discussed in studies II and IV further highlight crucial needs in the field 
of CVD. 
The basic CEAP classification is the recommended gold standard for documentation 
of CVD as it facilitates diagnosis and prioritization of the disease(53, 57). In study I 
where we investigated its use in clinical practice we saw that assessments differed 
considerably for both clinical class of CEAP and assessment for the medical 
indication for treatment between the investigators. Similar results were found in a 
recent study by Lattimer et al, where clinicians graded photographs of CVI patients 
according to the clinical class of CEAP(99).  
When analyzing the C classes separately, some difficulties stood out. Least 
agreement was seen for C3, although the number of patients was small. However 
when discussing the study results, it was obvious that we all found defining edema 
difficult. The definition of edema in the revised version of CEAP is “perceptible 
increase in volume of fluid in skin and subcutaneous tissue, characteristically 
indented with pressure. Venous edema usually occurs in ankle region, but may 
extend to leg and foot.”(76) Some patients in the study had minor edema in the 
ankle region indented by pressure from a sock, but this could also be considered 
physiological from prolonged standing; thus, the leg would be classified as C2 
instead of C3, edema. Another surprising difficulty, even if described previously, 
was in distinguishing widespread telangiectasies from hyperpigmentation i.e. C2 
from C4(100). 
In order to make the grading of venous symptoms more reliable, methods such as 
quality of life questionnaires and photoplethysmography have been used, but it has 
not been proven in larger studies that these methods really make the evaluation 
more consistent(68, 101).  
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The discrepancy in classifying according to CEAP brings to light two separate 
problems: scientific studies using the CEAP may not be reliable if the participating 
doctors are classifying differently, and in clinical daily life, patients may not be 
evaluated in an equitable way when it comes to reimbursement. 
In spite of the results in study I, the CEAP classification is the gold standard and 
necessary for prioritizing of patients.  
Endovenous ablation techniques have largely replaced open surgery of VV and in 
study II we try to evaluate mid-term outcomes on one of these techniques, namely 
EVLA. The National Institute for Health and Care Excellence has formed guidelines 
recommending minimally invasive techniques including EVLA, RFA and UGFS 
before surgery for treatment of VV and these guidelines have been challenged(102, 
103).  
In study II where the patient cohort includes patients with healed or active VU 
treated with EVLA for SVI, our results show that 84% of the treated legs still had a 
healed ulcer without recurrence after 3.5 years in a group of 170 patients where 16% 
were lost to follow-up. Complications were mostly minor and 15% had undergone 
repeat treatment of varicose veins. The study thus confirmed the findings of 
previous smaller studies with shorter follow-up(104). Many of the patients included 
were elderly with concomitant diseases, and we hope that the results of this and 
similar studies can encourage treating this particular group of patients more actively. 
Deep venous reflux, presence of PVI and/or varicose veins in the ulcer area and 
reduced ankle mobility are considered risk factors for ulcer recurrence(105, 106) 
and in this study this was confirmed in the comparison of groups but not in the 
logistic regression except for reduced ankle mobility.  
The role of PVI remains uncertain, there are no randomized trials with long-term 
follow-up showing that treating PVI reduces VU recurrence, even though several 
other studies have shown low recurrence rates(100, 107, 108). Presumably, patients 
with active or previous VU are more vulnerable even for modest remaining venous 
reflux in the area, PVI or other, and thus could benefit more from radical treatment 
than VV patients without skin changes. 
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A remarkable finding in study II was that all C6 legs had healed their original VU at 
some time before the study examination, after which it recurred in 14 patients. In 
most reports a certain percentage will not heal unless complete eradication of 
venous reflux and on-going ambulatory compression therapy. This result may be 
due to patient selection, presumably patients with giant ulcers of long-standing 
duration were not referred to the clinic and few patients with a history of DVT were 
included.  
The strength of this study is that EVLA was performed in clinical practice with no 
special care or follow-up for VU patients and even so the recurrence rate was low.  
A limitation with the study was that we did not know how much the added 
treatments of local varicosities and PVI improved the long term results in terms of 
ulcer healing and recurrence, and in the medical records it was not specified exactly 
how many perforators and VV in the ulcer area were treated.  
CVD being an inflammatory disease, markers such as albumin, fibrinogen, d-dimer 
and leucocyte counts have been studied to show if they can be used as predictors of 
progression of CVI(109). In study III, a cross-sectional study, we looked at E-XDP 
levels in patients with CVD. We found that these patients have elevated levels of 
circulating E-XDP compared to controls. This association between CVD and E-
XDP was confirmed after adjustment for age and gender but we have no evidence to 
conclude that such an association exists after adjusting for use of statins, 
anticoagulants and history of DVT.  
On comparison between groups with increasing severity of CVD, there was a 
significant difference between groups but the reason for the elevated E-XDP is 
unknown. It may be that the patients have thrombi in other parts of the body or 
micro thrombi in the vein wall that are also degraded by leucocyte elastase but other 
unknown sources of thrombi can not be neglected(110, 111). On multivariate 
analysis and after adjusting for use of statins, anticoagulants and history of DVT, 
there was no statistically significant association between E-XDP and CVI. Possible 
explanations to this is small sample size, too few controls or that there is no actual 
association between CVI and elevated levels of E-XDP. 
The main limitation with the study was that none of the controls were on statins or 
anticoagulants. Ideally we should have matched for age and for medications. 
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Another limitation was that we do not know if E-XDP levels increase over time with 
increasing disease severity. Therefore we need to follow these patients over time 
with further analysis. The most interesting patient group to follow would be C2 
patients with elevated E-XDP levels to see if they develop skin changes over time.  
In the fourth study our results demonstrate that the Swedish version of VEINES-
QOL/Sym, a disease specific HRQOL questionnaire for venous disease, is a valid 
and reliable scoring instrument for patients with CVD. The reliability was well 
supported by levels of Cronbach’s alpha above 0.8 for VEINES-QOL/Sym and 
there were significant correlations between all the RAND-36 subscales and the 
VEINES-QOL/Sym scores. These results are similar to findings in the original study 
and others(112-114). 
The C-class of the CEAP-classification had no significant correlation with the 
VEINES-QOL or VEINES-Sym scores but there was a trend for poorer outcome for 
VEINES-QOL with increasing disease severity. The reason for this finding raises 
the question whether it is the CEAP classification with inherent difficulties as 
discussed in study I or problems with the VEINES-QOL/Sym. Despite this result we 
still believe that PROMs are necessary as a complement to clinical severity scores 
such as VCSS.  
In our study, we used the RAND-36 questionnaire, which is similar to the SF-36 
except for differences in the scoring of general health and bodily pain, and in 
Swedish RAND-36 has a slightly modernized wording(115, 116). Our results 
concur with the original study with regard to construct validity(112). Generic 
instruments such as the RAND-36 are regularly used in venous disease studies and 
in clinical practice but disease specific instruments have the superiority of 
differentiating between diseases(55). 
The exploratory factor analysis was consistent with the findings in the Dutch study 
with similar factor loading patterns(98). Only one item loaded below the cut-off of 
0.35 but since the reliability analysis didn’t show a low alpha value, we chose to 
keep the item. 
A limitation of our study was that we weren’t able to assess test–retest reliability of 
the VEINES-QOL/Sym, which is an indicator of the stability of a measuring 
instrument.  
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METHODOLOGICAL CONSIDERATIONS 
All the studies included in this thesis are observational studies as opposed to 
experimental studies. 
Observational studies (OS) are the kind where the researcher systematically 
collects information but does not alter what occurs(117). Types of OS include 
cohort, cross-sectional and case-control studies.  
Cohort studies allow you to study changes and to establish the time-sequence in 
which things occur. They are like cross-sectional studies but extend over time. This 
permits study of cause. Disadvantages of this type of study are the need for a large 
sample size and very long follow-up times that are not only time consuming but also 
increase the risk of losing subjects to follow-up.  
In cross-sectional studies (Studies I, III and IV) you draw a random sample of 
people and record information about their health in a systematic manner. This type 
of study allows for comparison between study subjects with and without the disease. 
A disadvantage of this study type is causation; you do not know what came first.  
Case-control studies are more practical studies but are retrospective which means 
many disadvantages. The obvious advantage is that this type of study can be done 
faster and more cheaply than a cohort study. However, it may be difficult to collect 
the information you require on past exposures, and there may be other ways in 
which the cases and controls differ. Ways of avoiding this is by ensuring greater 
comparability between the two groups, and thereby avoid confounding bias; the 
controls could be matched for sex and age to the cases. 
Types of bias that can occur in OS are confounding and selection bias. 
Confounding occurs when there is a failure to adjust for common causes of both the 
exposure and the outcome(118). In both studies II and III this was an issue that we 
tried to adjust for by using multivariate analysis. During the selection of predictors 
to include in the multivariate regression models, we included well established or 
probable causal factors and factors considered as clinically relevant. This was done 
without regard to statistical significance or strength of their association with the 
predictor of primary interest and outcome.  
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In study II and III there was a difference between the univariate and multivariate 
analysis. The explanation was probably multi-factorial, collinearity between 
predictors in the multivariable regression and lack of power to detect a statistically 
significant association. In study III more confounders could have been included like 
other comorbidities including diabetes, heart disease or arterial disease, as these 
could be residual confounders that can never completely be ruled out.  
Selection bias is the systematic error that results from the way subjects are selected 
into the study or because there are selective losses of subjects before data 
analysis(119). This kind of bias together with confounding is the main obstacle for 
high validity in a study. In cohort studies, the primary sources of selection bias are 
loss to follow-up, withdrawal from the study, or nonresponse. Studies II and III 
were both vulnerable for this bias.  
In study II, patients were identified from the clinics quality registry, procedure 
codes for EVLA and diagnosis codes for venous ulceration in the medical records. 
Between the time of surgery and time of study the clinic changed it’s journal 
system, to minimize the risk of losing patients between system changes, we 
searched according the criteria named above in both old and new journal systems 
but this wouldn’t guarantee losing patients to misclassification. Misclassification in 
this case would be patients with VU but treated and given a surgical code other than 
EVLA or patients wrongly diagnosed. Other reasons for bias could be either that the 
patients suffered complications and sought care else where, or recurred in ulcer 
disease but chose not to come back to the clinic or moved away and for that reason 
could not be invited for follow-up.  
In study III most patients were elderly and we had a small control group so these 
facts could affect our findings. In cross-sectional studies, the primary source of 
selection bias is “selective survival.” Study III could theoretically suffer from this 
bias but since near to none patients die from CVD, this is a bias we didn’t have to 
take into consideration in our study.  
 
 
 
 
 CONCLUSIONS 
 
The present thesis has demonstrated that: 
Ø The reproducibility of the clinical class of CEAP when deciding medical 
indication for treatment is generally moderate. This may be due to inherent 
difficulties in the CEAP, lack of specific training, or the simultaneous 
assessment of reimbursement that may influence the clinical classification. 
Ø Endovenous laser ablation of superficial venous insufficiency in patients 
with healed or active venous ulcers confers both ulcer healing and low 
recurrence rates in a majority of patients with a low rate of complications 
and a modest rate of re-interventions.  
Ø There is an association between elevated levels of E-XDP and increasing 
disease severity in CVD.  
Ø The VEINES-QOL/Sym-Swe is a valid HRQOL instrument for CVD and 
confirms previous studies validating the original English version.  
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FUTURE PERSPECTIVES 
 
CVD and its most severe form VU probably consume more resources from society 
than funds allocated to research within the field. The “Cinderella” of surgery has 
despite that managed to intrigue my curiosity and further broaden my knowledge on 
the subject. The prevalence of CVD doesn’t seem to be decreasing and globally we 
are becoming more aware of its scope and need for further epidemiological studies. 
With this background, it is obvious that future studies are a necessity. 
Our findings in study I invite for a study where we train the investigators in the C-
class of CEAP prior to a similar study as study I. Another kind of study would be 
one where the investigators weren’t required to make a simultaneous decision on 
medical indication for reimbursement while grading with CEAP.  
Treatment with EVLA showed good mid-term ulcer recurrence results but a 
randomized controlled study comparing open surgery vs EVLA and compression vs 
EVLA may better answer the question about the efficacy of endovenous methods in 
treating patients with healed or active venous ulcers. 
Our study on a potential biomarker as a predictor of presence or disease severity 
causes speculation that the increased levels of E-XDP increase over time with 
increasing disease severity. A longitudinal follow-up study where E-XDP and other 
biomarkers are taken in C2 patients with elevated E-XDP and following them to see 
if they develop VU could possibly answer this question. 
Further, with emerging new treatments and evaluation of their effects, quality of life 
instruments are an appropriate way of doing so. In Sweden there is currently no 
disease-specific HRQoL instrument and after translation of the VEINES-QOL/Sym 
into a Swedish version, we see the need to modify it into a short version that is more 
convenient in clinical practice. This will also allow for more studies on CVD where 
a disease-specific instrument is available. A shortcoming with our study was that we 
didn’t assess test–retest reliability of the VEINES-QOL/Sym. We therefore plan a 
later study to answer the question of reproducibility. In addition, we found poor 
correlation between the VEINES-QOL/Sym and CEAP, which has its shortcomings 
as described above, and this brings reason to study the correlation between 
VEINES-QOL/Sym and duplex or PPG findings. 
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SAMMANFATTNING PÅ SVENSKA 
 
Kronisk venös sjukdom (CVD) är så vanligt förekommande att gränsen mellan 
normalvariant och sjukdomstillstånd är flytande. Enligt moderna studier har c:a en 
tredjedel av en västerländsk befolkning varicer. Benämningen kronisk venös 
insufficiens (CVI) hänvisas till den mer avancerade formen av CVD och yttrar sig 
dels som venösa hudförändringar såsom eksem, missfärgning och inflammationer 
vilket förekommer i 7 % och dels som bensår och förekommer i 1 % av alla med 
CVD. Omkostnaderna för bensår (varav venösa bensår är i majoritet) beräknas till 1-2 
% av EUs totala hälso- och sjukvårdsbudget. Venösa bensår är ofta smärtsamma och 
långvariga, och medför höga personalkostnader pga. omläggningar och 
kompressionslindning. 
Den klassifikation som används internationellt för att klassificera venös sjukdom, den 
kliniska C-delen av CEAP (Clinical Etiology Anatomy Pathophysiology), ligger till 
grund för landstingets rekommendation av vilka varicer som ska opereras på 
medicinsk indikation men är dåligt utvärderad trots att den används i nästan alla 
vetenskapliga studier om venös insufficiens. 
Det senaste decenniet har det blivit allt vanligare att traditionell åderbråckskirurgi 
ersätts med lasermetoder där åderbråcken bränns inifrån istället för att tas bort, s.k. 
endovenös laser. Metoden har vissa fördelar då den kan utföras mer skonsamt och 
därmed kan även äldre och sköra bensårspatienter behandlas. Enligt nyliga studier är 
metoden troligen likvärdig på sikt med vanlig kirurgi, men konvalescensen är kortare. 
Det är dock inte undersökt om själva läkningsprocessen för venösa bensår påverkas. 
I denna avhandling var övergripande målet att undersöka möjligheter att förbättra 
prioritering samt utredning och kirurgisk behandling av patienter med åderbråck som 
har eller löper risk att utveckla venösa sår. Mer specifikt undersöktes (I) om CEAP-
klassifikationen kan användas med god överensstämmelse mellan olika bedömare, 
(II) medför variceroperation med endovenös laser varaktig sårläkning på patienter 
med venösa sår, (III) om markören XDP i plasma skiljer sig mellan patienter utan 
venös sjukdom och med olika grad av hudförändringar vid kronisk venös insufficiens 
och (IV) om kan man översätta och validera ett sjukdomsspecifikt 
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livskvalitetsformulär från engelska till svenska, nämligen VEINES-QOL/Sym. 
Resultat från studierna som ingick sammanfattas nedan. 
Studie I visade att när tre av varandra oberoende kirurger klassificerade 106 ben på 78 
patienter avseende klinisk svårighetsgrad enligt CEAP klassifikationen och avseende 
medicinsk indikation för ingreppet förelåg endast en måttlig överensstämmelse.  
Studie II visade att 84 % av 170 patienter (195 ben) har läkta bensår utan recidiv 3,5 
år efter operation och med få komplikationer. Vår studie speglar den kliniska 
verkligheten med positiva resultat. Nedsatt rörelseförmåga i vristen var en signifikant 
riskfaktor för recidiv av bensår i vår studie som tidigare visat. 
Studie III visade att det finns en koppling mellan förhöjda plasma nivåer av E-XDP 
och CVD. För att kunna använda E-XDP som biomarkör i diagnostiskt syfte av CVD 
patienter kräver dock ytterligare studier.  
I studie IV visade resultaten att det finns en utmärkt intern tillförlitlighet för 
både VEINES-QOL och VEINES-Sym. Båda VEINES-QOL och VEINES-Sym 
korrelerade väl till alla domän i RAND-36 (generisk livskvalitetsformulär), 
demonstrerande god konstruktions validitet.  
Sammanfattningsvis påvisar resultaten i denna avhandling att C-delen av CEAP är 
fortsatt gold standard vid diagnostisering av CVD trots godtycklig reproducerbarhet 
och bensårs patienter som behandlas med EVLA får en varaktig sårläkning med få 
komplikationer. Vidare verkar E-XDP ha en positiv korrelation med ökande grad av 
CVD. Sist men inte minst, Svenska versionen av VEINES-QOL/Sym är en validerad 
livskvalitets instrument för CVD och kan användas kliniskt och för forskning.
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